跳至主要内容
临床试验/NCT01053559
NCT01053559已完成不适用

Open Label Investigator Initiated, Single Site Study of Mucosal Healing in Patients With Small Bowel Crohn's Disease Treated With Certolizumab Pegol (Cimzia) Assessed by Wireless Capsule Endoscopy

Shafran Gastroenterology Center1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2010年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
15
试验地点
1
主要终点
Mucosal Healing

研究概览

简要总结

Wireless Capsule Endoscopy has been the most reliable diagnostic standard for small bowel Crohn's disease. Endoscopic healing is an important endpoint to measure response to treatment.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults aged 18-70 with confirmed Crohn's disease that includes small bowel disease
  • Moderately to severely active disease (CDAI score >220 and < 450)
  • Stable doses of steroids, 5-ASA, antibiotics, Immunosuppressants

排除标准

  • Any and all contraindications to the use of certolizumab pegol (including but not limited to hepatitis, infection, abscess, malignancy, congestive heart failure [CHF], cytopenia)
  • Small bowel obstruction, stricture, or any contraindication for capsule endoscopy
  • Previous treatment with certolizumab pegol
  • Are pregnant or lactating

研究组 & 干预措施

certolizumab pegol

Other

Subjects will receive FDA approved Cimzia injections as indicated on the product label. Subjects will undergo 3 wireless capsule endoscopies, one at screening,Day 84 and Day 168 as well as monthly bloodwork.

干预措施: certolizumab pegol (Drug)

结局指标

主要结局

Mucosal Healing

时间窗: 180 Days

次要结局

  • C-Reactive Protein (CRP) Level(180 Days)

研究者

发起方
Shafran Gastroenterology Center
申办方类型
Other
责任方
Principal Investigator
主要研究者

Ira Shafran M.D.

Principal Investigator

Shafran Gastroenterology Center

研究点 (1)

Loading locations...

相似试验